Condition: In-stent Restenosis · Sponsor: Fu Wai Hospital, Beijing, China
This study is aimed at making a comparison of the safety and efficacy of standard drug therapy (control group), standard drugs combined with lose-dose colchicine therapy (colchicine group) and standard drug combined with prednisone therapy (prednisone group) in patients with coronary heart disease who suffered from recurrent In-stent restenosis (RISR).
This description comes directly from the study's public registry record.
Haiyan Qian · +8613811386143 · ahqhy712@163.com
Zhiyao Wei · +8615521192379 · weizhiyaoyx@163.com
Always discuss trial participation with your own doctor first.
| Beijing Anzhen Hospital, Capital Medical University | Beijing, Beijing Municipality, China | Recruiting |
| Beijing Friendship Hospital | Beijing, Beijing Municipality, China | Not Yet Recruiting |
| Beijing Luhe Hospital | Beijing, Beijing Municipality, China | Recruiting |
| Fuwai Hospital | Beijing, Beijing Municipality, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06090890